Reata: A "Show Me" Story Showing the Results and with Two Upcoming Catalysts
thenonconsensus.substack.com
Strong omaveloxolone results in FA was a surprise and could generate $1B+ in sales. Importantly, their Nrf2 activators could potentially treat many other neurodegenerative indications beyond FA Moving forward, attention will shift back to bardoxolone with Alport Syndrome readout expected this quarter, and CTD-PAH by 1H20
Reata: A "Show Me" Story Showing the Results and with Two Upcoming Catalysts
Reata: A "Show Me" Story Showing the Results…
Reata: A "Show Me" Story Showing the Results and with Two Upcoming Catalysts
Strong omaveloxolone results in FA was a surprise and could generate $1B+ in sales. Importantly, their Nrf2 activators could potentially treat many other neurodegenerative indications beyond FA Moving forward, attention will shift back to bardoxolone with Alport Syndrome readout expected this quarter, and CTD-PAH by 1H20